Bicara Therapeutics (BCAX) Operating Income (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Operating Income of -$60.2 million for Q1 2026, down 44.16% year-over-year from -$107.9 million in Q1 2025, and down 46.5% quarter-over-quarter from -$41.1 million in Q4 2025.
Bicara Therapeutics (BCAX) Operating Income (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Operating Income history runs 4 years deep, the most recent figure standing at -$60.2 million for Q1 2026.
- In Q1 2026, Operating Income fell 44.16% year-over-year to -$60.2 million; the TTM figure through Mar 2026 stood at -$174.1 million (down 59.98% YoY), while the FY2025 annual figure was -$155.6 million, down 88.87% from the prior year.
- Operating Income for Q1 2026 stood at -$60.2 million, down from -$41.1 million in the prior quarter.
- The five-year high for Operating Income was -$9.5 million in Q3 2023, with the low at -$60.2 million in Q1 2026.
- The 4-year median for Operating Income is -$26.6 million (2024), against an average of -$29.2 million.
- The sharpest annual moves came in 2025 and 2026: Operating Income tumbled 171.81% in 2025, then slumped 44.16% in 2026.
- Bicara Therapeutics' Operating Income stood at -$13.7 million in 2023, then tumbled by 94.62% to -$26.6 million in 2024, then sank by 54.38% to -$41.1 million in 2025, then plunged by 46.5% to -$60.2 million in 2026.
- Business Quant data shows BCAX's Operating Income at -$60.2 million in Q1 2026, -$41.1 million in Q4 2025, and -$40.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | -59.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -59.95 Mn |
| Mar 31, 2026 | -60.24 Mn |
| Dec 31, 2025 | -41.12 Mn |
| Sep 30, 2025 | -40.68 Mn |
| Jun 30, 2025 | -32.02 Mn |
| Mar 31, 2025 | -41.79 Mn |
| Dec 31, 2024 | -26.64 Mn |
| Sep 30, 2024 | -20.63 Mn |
| Jun 30, 2024 | -19.75 Mn |
| Mar 31, 2024 | -15.37 Mn |
| Dec 31, 2023 | -13.69 Mn |
| Sep 30, 2023 | -9.53 Mn |